- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04126005
Natural History Study of Patients With Canavan Disease
July 10, 2023 updated by: Aspa Therapeutics
A Combination Retrospective Medical History and Prospective Observational Study of Patients With Canavan Disease for Assessment of Natural History of Canavan Disease
This study uses medical records that allow retrospective data extraction of critical milestone and motor function data.
In addition, prospective assessments collect data relevant to the natural history of Canavan disease in children.
Study Overview
Status
Recruiting
Conditions
Detailed Description
The CANinform natural history study is the first multinational effort to rigorously gather both retrospective and prospective data from this patient population.
Data collection includes extraction of retrospective data from medical records of living and deceased patients, and collection of prospective, longitudinal data from living patients and their parent(s)/caregiver(s).
Motor function assessments are performed remotely in the home via video or in the clinic by qualified study team members.
Families will be invited to attend clinic visits and/or will be followed remotely by the clinical site for approximately 3 years.
Study Type
Observational
Enrollment (Estimated)
40
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Michelle Nelken
- Phone Number: 833-764-2267 or 617-861-4617
- Email: CANinform@aspatx.com
Study Contact Backup
- Name: clinicaltrials@aspatx.com
Study Locations
-
-
-
Hamburg, Germany, 20246
- Recruiting
- University Medical Center Hamburg-Eppendorf
-
Principal Investigator:
- Annette Bley, MD
-
Contact:
- Ina Ulrichs
- Phone Number: 0049(0) 40 7410- 59060
- Email: info.ld@uke.de
-
-
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Recruiting
- Massachusetts General Hospital
-
Principal Investigator:
- Florian Eichler, MD
-
Contact:
- Damilola Oje
- Phone Number: 617-724-6510
- Email: doje@mgh.harvard.edu
-
-
New York
-
New York, New York, United States, 10016
- Withdrawn
- NYU Langone Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Probability Sample
Study Population
Living and deceased patients with Canavan disease
Description
Inclusion Criteria:
- Meet age criteria of a specific cohort. Note: In the case of a deceased patient whose parent(s) and/or legal guardian(s) have provided informed consent for study participation, the Investigator will review the patient's medical record(s) to determine study eligibility.
- Confirmed clinical and biochemical diagnosis of Canavan disease.
- Available medical records since birth that permit documentation of disease characteristics and developmental milestones.
- Parent and/or legal guardian is able to read, understand, and sign the informed consent.
Exclusion Criteria:
1. Patient does not meet the Inclusion Criteria.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Other
Cohorts and Interventions
Group / Cohort |
---|
Cohort 5 (Deceased)
• The patient's medical history records will be reviewed.
In addition, a parent interview will be performed.
|
Cohort 1 (Age < 18 Months)
|
Cohort 2 (Age ≥ 18 Months - 3 Years)
|
Cohort 3 (Age > 3 - 5 Years)
|
Cohort 4 (Age > 5 Years)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To characterize the natural history of Canavan disease
Time Frame: approximately 3 years
|
To enhance the understanding of the natural history of Canavan disease through retrospective data collection from patient medical records and prospective data collection from living patients, including: phenotypic characteristics and variability, genotype characteristics and variability, and disease progression and natural history.
|
approximately 3 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 10, 2019
Primary Completion (Estimated)
December 31, 2024
Study Completion (Estimated)
April 30, 2025
Study Registration Dates
First Submitted
October 10, 2019
First Submitted That Met QC Criteria
October 11, 2019
First Posted (Actual)
October 14, 2019
Study Record Updates
Last Update Posted (Actual)
July 12, 2023
Last Update Submitted That Met QC Criteria
July 10, 2023
Last Verified
July 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Metabolic Diseases
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Demyelinating Diseases
- Genetic Diseases, Inborn
- Neurodegenerative Diseases
- Metabolism, Inborn Errors
- Heredodegenerative Disorders, Nervous System
- Brain Diseases, Metabolic
- Brain Diseases, Metabolic, Inborn
- Leukoencephalopathies
- Hereditary Central Nervous System Demyelinating Diseases
- Canavan Disease
Other Study ID Numbers
- CVN-101
- CANinform (Other Identifier: Aspa Therapeutics)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Data will be made available for researchers using a defined process.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Canavan Disease
-
Sheba Medical CenterUnknownInfantile Canavan Disease | Deficiency Disease, AspartoacylaseIsrael
-
NYU Langone HealthUniversitätsklinikum Hamburg-EppendorfCompleted
-
Shaare Zedek Medical CenterUnknown
-
Myrtelle Inc.RecruitingCanavan DiseaseUnited States
-
University of FloridaUniversity of Miami; University of Massachusetts, WorcesterNo longer available
-
Assistance Publique - Hôpitaux de ParisEuropean Leukodystrophy AssociationWithdrawnDeficiency Disease | Canavan Disease | Infantile | Aspartoacylase | Leukodystrophy, Spongiform
-
Aspa TherapeuticsRecruitingCanavan DiseaseUnited States
-
McGill University Health Centre/Research Institute...CompletedFamilial Dysautonomia | Tay Sachs Disease | Canavan DiseaseCanada
-
Children's Hospital of PhiladelphiaIllumina, Inc.Active, not recruitingMucopolysaccharidoses | Leukodystrophy | Adrenoleukodystrophy | Adrenomyeloneuropathy | X-linked Adrenoleukodystrophy | Gangliosidoses | Metachromatic Leukodystrophy | Krabbe Disease | Refsum Disease | Cadasil | Sjogren-Larsson Syndrome | Allan-Herndon-Dudley Syndrome | White Matter Disease | GM2 Gangliosidosis | Zellweger... and other conditionsUnited States
-
ProgenaBiomeRecruitingAlzheimer Disease | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3 | Alzheimer Disease 4 | Alzheimer Disease 7 | Alzheimer Disease 17 | Alzheimer Disease 5 | Alzheimer Disease 6 | Alzheimer Disease 8 | Alzheimer Disease 10 | Alzheimer... and other conditionsUnited States